Compound Detail
CHEMBL223360
LINIFANIB 🧪 Phase III
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
🧪 Phase III
Basic Information
| ChEMBL ID | CHEMBL223360 |
| Name | LINIFANIB |
| Phase | Phase III |
| Structure Type | MOL |
| InChI Key | MPVGZUGXCQEXTM-UHFFFAOYSA-N |
148
Targets
336
Activities
3
Assay Types
19
PK Parameters
20
Publications
5
Known Names
10
Indications
4
Mechanisms
Molecular Properties
375.4
MW (Da)
4.90
ALogP
3
HBA
4
HBD
95.8
PSA (Ų)
0.41
QED
0
Ro5 Violations
3
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| Chirality | Achiral |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Macrophage colony stimulating factor receptor inhibitor | INHIBITOR | Macrophage colony-stimulating factor 1 receptor | ✓ | ✓ |
| Tyrosine-protein kinase receptor FLT3 inhibitor | INHIBITOR | Receptor-type tyrosine-protein kinase FLT3 | ✓ | ✓ |
| Platelet-derived growth factor receptor inhibitor | INHIBITOR | Platelet-derived growth factor receptor | ✓ | ✓ |
| Vascular endothelial growth factor receptor inhibitor | INHIBITOR | Vascular endothelial growth factor receptor | ✓ | ✓ |
Indications
Carcinoma, Hepatocellular Breast Neoplasms Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Colonic Neoplasms Colorectal Neoplasms Macular Degeneration Rectal Neoplasms Endometriosis Neoplasms
Activity Summary
Kd 190 meas. best 9.2
IC50 79 meas. best 8.64
Ki 67 meas. best 9.0
Target Activity Profile
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| AUC | 9197.55 | ng.hr.mL-1 | Mus musculus |
| AUC | 6800.0 | ng.hr.mL-1 | Rattus norvegicus |
| AUC | 600.0 | ng.hr.mL-1 | Macaca fascicularis |
| AUC | 1500.0 | ng.hr.mL-1 | Canis lupus familiaris |
| AUC | 7170.33 | ng.hr.mL-1 | Mus musculus |
| AUC | 9197.55 | ng.hr.mL-1 | Mus musculus |
| CL | 3.3 | mL.min-1.kg-1 | Rattus norvegicus |
| CL | 8.2 | mL.min-1.kg-1 | Macaca fascicularis |
| CL | 7.2 | mL.min-1.kg-1 | Canis lupus familiaris |
| CL | 18.33 | mL.min-1.kg-1 | Mus musculus |
| F | 100.0 | % | Mus musculus |
| F | 27.0 | % | Rattus norvegicus |
| F | 10.6 | % | Macaca fascicularis |
| F | 47.0 | % | Canis lupus familiaris |
| T1/2 | 3.6 | hr | Rattus norvegicus |
| T1/2 | 3.1 | hr | Macaca fascicularis |
| T1/2 | 2.0 | hr | Canis lupus familiaris |
| T1/2 | 1.7 | hr | Mus musculus |
| Vd | 2.7 | L.kg-1 | Mus musculus |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
| PubMed | DOI | Target Context | # Activities |
|---|---|---|---|
| 22037378 | 10.1038/nbt.1990 | Tyrosine-protein kinase ABL1 | 15 |
| 22037378 | 10.1038/nbt.1990 | Epidermal growth factor receptor | 12 |
| 22037378 | 10.1038/nbt.1990 | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform | 10 |
| 18183025 | 10.1038/nbt1358 | Epidermal growth factor receptor | 10 |
| 22037378 | 10.1038/nbt.1990 | Mast/stem cell growth factor receptor Kit | 8 |
| 26254279 | 10.18632/oncotarget.4214 | Unchecked | 8 |
| 22037378 | 10.1038/nbt.1990 | Receptor-type tyrosine-protein kinase FLT3 | 7 |
| 18183025 | 10.1038/nbt1358 | Tyrosine-protein kinase ABL1 | 7 |
| 28787156 | 10.1021/acs.jmedchem.7b00794 | Protein smoothened | 6 |
| 18183025 | 10.1038/nbt1358 | Receptor-type tyrosine-protein kinase FLT3 | 6 |
| 18260617 | 10.1021/jm701096v | Mus musculus | 6 |
| 18183025 | 10.1038/nbt1358 | Mast/stem cell growth factor receptor Kit | 5 |
| 29191878 | 10.1126/science.aan4368 | Unchecked | 5 |
| 35863236 | 10.1016/j.bmc.2022.116937 | MV4-11 | 5 |
| 17343372 | 10.1021/jm061280h | Rattus norvegicus | 5 |
| 17343372 | 10.1021/jm061280h | Cynomolgus monkey | 5 |
| 17343372 | 10.1021/jm061280h | Canis familiaris | 5 |
| 22037378 | 10.1038/nbt.1990 | Proto-oncogene tyrosine-protein kinase receptor Ret | 4 |
| - | 10.6019/CHEMBL4495565 | SARS-CoV-2 | 4 |
| 17343372 | 10.1021/jm061280h | Plasma | 4 |
Data from ChEMBL 36 via Core Engine